Press Releases Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Real-time Estimate Cboe BZX Other stock markets 12:11:38 2024-04-30 pm EDT			5-day change	1st Jan Change
4.77 ^USD	0.00%		-2.97%	-8.82%

Apr. 25	Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	CI
Apr. 01	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	Apr. 25	BU
Vistagen to Present at the 2024 Anxiety and Depression Association Conference	Apr. 10	AQ
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference	Apr. 09	BU
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	Apr. 01	BU
Vistagen to Present at Stifel 2024 Virtual CNS Days	Mar. 11	BU
Vistagen to Present at TD Cowen 44th Annual Health Care Conference	Feb. 28	BU
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update	Feb. 13	BU
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024	Feb. 06	BU
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	Dec. 27	BU
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results	Nov. 09	BU
Vistagen to Present at Stifel 2023 Healthcare Conference	Nov. 08	BU
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences	Nov. 07	BU
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023	Nov. 06	BU
VISTAGEN THERAPEUTICS : INDEMNIFICATION AGREEMENT - Form 8-K	23-10-26	PU
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit	23-10-05	BU
Vistagen Announces Pricing of $100 Million Underwritten Offering	23-10-02	BU
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder	23-09-12	BU
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	23-09-06	AQ
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	23-09-05	BU
Vistagen Appoints Cindy Anderson as Chief Financial Officer	23-08-22	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Press Releases

Filters